Queen's Gazette | Queen's University

Search form

News Release - Tragically Hip recognized for supporting brain cancer research

Tuesday, April 4, 2017

Kingston – Today, the Canadian Cancer Society (CCS) recognized Kingston hometown heroes the Tragically Hip for their support of brain cancer research. A commemorative plaque was presented to the band in honour of their support for cancer clinical trials at the Canadian Cancer Trials Group (CCTG).

CCTG, housed at Queen’s University in Kingston, is supported by a core grant from the Canadian Cancer Society.

Since the announcement last year that the Hip’s frontman Gord Downie has glioblastoma (an aggressive form of brain cancer), many Canadians have shown their support through donations to CCS.

“The Canadian Cancer Society is very grateful to the Tragically Hip and their generous fans for this donation of $400,000 for brain cancer research,” says Lynne Hudson, CCS president and CEO. “Clinical trials offer hope for people with cancer and provide an opportunity for researchers to find better treatments for others in the future. CCS is proud to be able to support clinical trials at CCTG across the country through donations from the public.”

Clinical trials can help patients directly. For example, in collaboration with colleagues in Europe, CCTG conducted a trial to see if a chemotherapy drug called temozolomide along with radiation following surgery for glioblastoma could improve survival. The trial showed positive results, and this combination therapy is what Downie received at Sunnybrook Hospital in Toronto.

Every day about 25 Canadians are diagnosed with some form of brain tumour. Glioblastoma is an aggressive disease and is the most common primary brain cancer in adults. Unfortunately, most adults with a diagnosis of glioblastoma survive only 1–2 years after diagnosis.

“This is a great example of the Faculty of Health Sciences’ vision in action: to ask questions, seek answers, advance care and inspire change,” says Richard Reznick, Dean of Health Sciences. “Queen’s is proud to serve as host to CCTG’s cutting edge research; it is humbling to have this research happening right in our own backyard.”

“As researchers, our greatest achievement is to see patients with cancer benefit from treatments that were proven effective by the work we do at CCTG,” says Janet Dancey, the group’s director. “Building on past international research successes, CCTG is looking at future clinical trials using promising treatments, including viral therapies and drugs to stimulate the immune system.”

Donations to the Canadian Cancer Society for brain cancer research will allow researchers to make real and significant progress against this disease.  Read more.

-30-

The Canadian Cancer Society is a national, community-based organization of volunteers whose mission is to eradicate cancer and enhance the quality of life of people living with cancer. Thanks to our donors and volunteers, CCS has the most impact, against the most cancers, in the most communities in Canada. Make your donation today at www.cancer.ca

 

The Canadian Cancer Trials Group (CCTG) is a cancer clinical trials research cooperative that runs phase I-III trials to test anti-cancer and supportive therapies in 80 institutions across Canada and internationally. CCTG is a national program of the Canadian Cancer Society. From its centre at Queen’s University in Kingston, Ontario, CCTG has supported over 500 trials in over 40 countries aimed at improving survival rates and quality of life for cancer patients.

 

Contact
Anne Craig, Media Relations Officer
Queen’s University
613-533-2877
anne.craig@queensu.ca

Lisa Callahan, Communications leader
Canadian Cancer Trials Group
613-533-6000 x 74483
lcallahan@ctg.queensu.ca

Attachments